RT @NHLBI_Translate: In #JACC article, Dr. Greg Fonarow @gcfmd & colleagues address #barriers in #development and #Implementation and what…
RT @NHLBI_Translate: In #JACC article, Dr. Greg Fonarow @gcfmd & colleagues address #barriers in #development and #Implementation and what…
In #JACC article, Dr. Greg Fonarow @gcfmd & colleagues address #barriers in #development and #Implementation and what we can learn from #oncology to overcome #challenges in developing novel therapies for #cardiovascular diseases. #CVD #Cancer @US_FDA
Study in #JACC shows that, between 2010 and 2017, there were nearly 2.5 times as many #oncology FDA approvals as #CVD approvals. #Cancer #Barriers #Facilitators #Pathways #cardiovascular Seethe proposed bold vision: https://t.co/epQMMwi87B https://t.co/Ra
A bold new vision for #cardiovascular health! The CVD #Moonshot Program. See: https://t.co/epQMMwi87B #Barriers #Facilitators #Pathways #CancerMoonshot https://t.co/wy0VpU2Vx3
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @datsunian: Great commentary by @gcfmd etal on trajectories bw ❤️ & onc drug development. While justification/drive for onc drug approva…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @datsunian: Great commentary by @gcfmd etal on trajectories bw ❤️ & onc drug development. While justification/drive for onc drug approva…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @datsunian: Great commentary by @gcfmd etal on trajectories bw ❤️ & onc drug development. While justification/drive for onc drug approva…
If this is a concern in cardiology what about #nephrology
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @datsunian: Great commentary by @gcfmd etal on trajectories bw ❤️ & onc drug development. While justification/drive for onc drug approva…
RT @datsunian: Great commentary by @gcfmd etal on trajectories bw ❤️ & onc drug development. While justification/drive for onc drug approva…
Great commentary by @gcfmd etal on trajectories bw ❤️ & onc drug development. While justification/drive for onc drug approvals can be controversial (& makes #cardioonc interesting when they go real world) more advocacy is needed in our field. @Card
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
RT @JACCJournals: Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co…
Why is cardiovascular drug development so far behind oncology drug development, and what can we do about it? https://t.co/ja1u2DgPHl #JACCBTS #OpenAccess https://t.co/NYtQjZSnZY